Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) EPS (Basic) (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of EPS (Basic) data on record, last reported at -$0.51 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 86.29% year-over-year to -$0.51; the TTM value through Dec 2025 reached -$2.88, up 62.2%, while the annual FY2025 figure was -$8.36, 58.49% up from the prior year.
  • EPS (Basic) reached -$0.51 in Q4 2025 per INM's latest filing, down from -$0.44 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.39 in Q2 2024 and bottomed at -$15.24 in Q3 2023.
  • Average EPS (Basic) over 5 years is -$3.77, with a median of -$3.14 recorded in 2024.
  • The widest YoY moves for EPS (Basic): up 753.57% in 2024, down 496.67% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at -$7.86 in 2021, then skyrocketed by 88.42% to -$0.91 in 2022, then crashed by 307.69% to -$3.71 in 2023, then decreased by 0.27% to -$3.72 in 2024, then surged by 86.29% to -$0.51 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.51 in Q4 2025, -$0.44 in Q3 2025, and -$0.43 in Q2 2025.